DailyMed Advanced Search Medicines Micromedex UpToDate
Online Anticoagulation Information for Pharmacists and Patients
Anticoagulants from Wikipedia (antithrombics, fibrinolytic, and thrombolytics) are a class of drugs that work to prevent the coagulation (clotting) of blood. Such substances occur naturally in leeches and blood-sucking insects. A group of pharmaceuticals called anticoagulants can be used in vivo as a medication for thrombotic disorders. Some anticoagulants are used in medical equipment, such as test tubes, blood transfusion bags, and renal dialysis equipment.
Medications
Anticoagulants reduce blood clotting. This prevents deep vein thrombosis, pulmonary embolism, myocardial infarction and ischemic stroke.
Coumarins (vitamin K antagonists)
Further information: Vitamin K antagonist
These oral anticoagulants are derived from coumarin, which is found in many plants. A prominent member of this class is warfarin (Coumadin). It takes at least 48 to 72 hours for the anticoagulant effect to develop. Where an immediate effect is required, heparin must be given concomitantly. These anticoagulants are used to treat patients with deep-vein thrombosis (DVT), pulmonary embolism (PE) and to prevent emboli in patients with atrial fibrillation (AF), and mechanical prosthetic heart valves.
Adverse effects
Patients aged 80 years or more may be especially susceptible to bleeding complications, with a rate of 13 bleeds per 100 person-years. These oral anticoagulants are used widely as poisons for mammalian pests, especially rodents. (For details, see rodenticide and warfarin.) Depletion of vitamin K by Coumadin therapy increases risk of arterial calcification and heart valve calcification, especially if too much vitamin D is present.
Available agents
Low molecular weight heparin
Low molecular weight heparin, a more highly processed product, is useful as it does not require monitoring of the APTT coagulation parameter (it has more predictable plasma levels) and has fewer side effects.
Synthetic pentasaccharide inhibitors of factor Xa
Direct factor Xa inhibitors
Main article: Direct Xa inhibitor
Drugs such as rivaroxaban, apixaban and edoxaban work by inhibiting factor Xa directly (unlike the heparins and fondaparinux, which work via antithrombin activation). Also betrixaban (LY517717) from Portola Pharmaceuticals, darexaban (YM150) from Astellas and more recent TAK-442 letaxaban (Takeda) and eribaxaban (PD0348292) (Pfizer). The development of darexaban was discontinued in September 2011: in a trial for prevention of recurrences of myocardial infarction in top of dual antiplatelet therapy, the drug didn't work and the risk for bleeding was increased bij 300%. The development of letaxaban was discontinued for acute coronary syndrome in May 2011 following negative results from a Phase II study.
Heparin-induced thrombocytopenia (HIT)
Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count), due to the administration of various forms of heparin, an anticoagulant. HIT predisposes to thrombosis, the abnormal formation of blood clots inside a blood vessel, and when thrombosis is identified the condition is called heparin-induced thrombocytopenia and thrombosis (HITT). HIT is caused by the formation of abnormal antibodies that activate platelets. If someone receiving heparin develops new or worsening thrombosis, or if the platelet count falls, HIT can be confirmed with specific blood tests.
The treatment of HIT requires both protection from thrombosis and choice of an agent that will not reduce the platelet count further. Several agents exist for this purpose, mainly lepirudin and argatroban. While heparin was discovered in the 1930s, HIT was not reported until the 1960s and 1970s.
Treatment
Molecular structure of argatroban, a direct thrombin inhibitor used as an alternative to heparin in HIT. Given the fact that HIT predisposes strongly to new episodes of thrombosis, it is not sufficient to simply discontinue the heparin administration. Generally, an alternative anticoagulant is needed to suppress the thrombotic tendency while the generation of antibodies stops and the platelet count recovers. To make matters more complicated, the other most commonly used anticoagulant, warfarin, should not be used in HIT until the platelet count is at least 150 x 10^9/L because there is a very high risk of warfarin necrosis in people with HIT who have low platelet counts. Warfarin necrosis is the development of skin gangrene in those receiving warfarin or a similar vitamin K inhibitor. If the patient was receiving warfarin at the time when HIT is diagnosed, the activity of warfarin is reversed with vitamin K. Transfusing platelets is discouraged, as there is a theoretical risk that this may worsen the risk of thrombosis; the platelet count is rarely low enough to be the principal cause of significant hemorrhage.
Three agents are used to provide anticoagulation in patients with strongly suspected or proven HIT: danaparoid, lepirudin, and argatroban. These are alternatives to heparin therapy. Not all agents are registered in all countries. For instance, argatroban is not used in the United Kingdom and danaparoid is not available in the United States. Lepirudin production stopped on May 31, 2012. A fourth agent acting as a Factor Xa inhibitor also has an off label use for HIT treatment known as fondaparinux and is available and commonly used in the United States.
According to systematic review, patients treated with lepirudin for HIT showed a relative risk reduction of clinical outcome (death, amputation, etc.) to be 0.52 and 0.42 when compared to patient controls. In addition, patients treated with argatroban for HIT showed a relative risk reduction of the above clinical outcomes to be 0.20 and 0.18.
Direct thrombin inhibitors
Main article: direct thrombin inhibitor
Another type of anticoagulant is the direct thrombin inhibitor. Current members of this class include the bivalent drugs hirudin, lepirudin, and bivalirudin; and the monovalent drugs argatroban and dabigatran. An oral direct thrombin inhibitor, ximelagatran (Exanta) was denied approval by the Food and Drug Administration (FDA) in September 2004 and was pulled from the market entirely in February 2006 after reports of severe liver damage and heart attacks. In November 2010, dabigatran was approved by the FDA to treat atrial fibrillation.
Antithrombin protein therapeutics
The antithrombin protein itself is used as a protein therapeutic that can be purified from human plasma or produced recombinantly (for example, Atryn, which is produced in the milk of genetically modified goats.)
Antithrombin is approved by the FDA as an anticoagulant for the prevention of clots before, during, or after surgery or birthing in patients with hereditary antithrombin deficiency.
Other types of anticoagulants
Many other anticoagulants exist, for use in research and development, diagnostics, or as drug candidates.
Anticoagulation Related Websiles
AF Answers: What is Atrial Fibrillation
Agency for Healthcare Research and Quality: Blood Thinner Pills
American Stroke Association
Anticoagulant and Antiplatelet Drugs
Antithrombotic Therapy and Prevention of Thrombosis
Anticoagulant Treatment
Anticoagulation - American Heart Association
Anticoagulation Articles
Anticoagulation Resource Center
Anticoagulation Therapy - Anticoagulation Europe
ClotCare Online Resource
Coumadin (warfarin sodium tablet, USP) Crystalline
EHRA Practical Guide on the use of new oral anticoagulants
Guide to Anticoagulant Therapy: Heparin
Guidelines For Antithrombotic Therapy
LOVENOX® (enoxaparin sodium injection) Dosing for DVT
Lovenox® (enoxaparin sodium injection) Product Information
Lovenox (Enoxaparin Sodium Injection) Drug Information
MedicineNet.com: Warfarin (Coumadin)
New Oral Anticoagulants for Atrial Fibrillation
New oral anticoagulants: which one should my patient use?
Outpatient Management of Anticoagulation Therapy - American What is Pradaxa
Pharmacology –What’s New in Anticoagulation Medications
Pradaxa Information
Review: New Oral Anticoagulants for Afib, VTE, and ACS -
The Coalition to Prevent Deep-Vein Thrombosis (DVT)
XARELTO® (rivaroxaban)
XARELTO®
Warfarin and Beyond: An Update On Oral Anticoagulation Therapy
Adult Anticoagulation Orders Following Placement of Impella®
IMPELLA 2.5 ADDENDUM TO ADULT CRITICAL CARE ... - InfoClique
Use of the Impella 2.5 in High-Risk Percutaneous Coronary
Unfractionated Heparin Infusion Protocol - University Health System
Principles of Impella Cardiac Support - Cardiac Interventions Today
The Duration of Impella 2.5 Circulatory Support and Length of
Anticoagulation Protocols
Heparin & Enoxaparin - VUNeo.Org
Transition of Anticoagulants 2014 - Thomas Land Publishers
(BESt). Management of low molecular weight heparin therapy
University of Connecticut Health Center- John ... - Pharmacy
Anticoagulation Therapy Guidelines for Medical Indications
Guidelines For Antithrombotic Therapy
Guidelines for Deep Venous Thrombosis (DVT) Prophylaxis
Anticoagulation Bridging - Intermountain Physician
Pharmacokinetics of the low molecular weight heparin
Heparin Induced Thrombocytopenia Related Links
American Association of Blood Banks
American Red Cross
BleedingWeb.com
Bloodline
Blood management abstracts (SABM).
California Blood Bank Society
Factor VIIa
Haemophilia Forum
Heparin Induced Thrombocytopenia
International Society on Thrombosis and Haemostasis.
Irontherapy.org
Lipids Online
Management of anticoagulation, an anticoagulation management service.
DocMD's SpecialtyLinks
DocMD's Medline access page.
National Heart Lung and Blood Institute at the NIH
Network for Advancement of Transfusion Alternatives.
National Organization for Rare Disorders.
National Hemophilia Foundation's web site
Platelet inhibitors
Novoseven
Plasma Protein Therapeutics Association (PPTA)
Regional anesthesia guidelines
Resource guide
Scientific slides
Spanish language information and sites on hemostasis.
Society for the Advancement of Blood Management
CABG-consult.com.
Hemostasiscme.org.
Transfusion Medicine and Alternatives in Transfusion Medicine
Trigger
VascularWeb
Web based illustrations about hemostasis from diaPharma site.
Heparin Induced Thrombocytopenia.
Heparin Induced Thrombocytopenia (HIT)
Hit Related Links
American Red Cross
Frequently asked questions about HIT
HIT and cardiopulmonary bypass
HIT guidelines
HIT information
Incidence of HIT
Heparin Induced Thrombocytopenia
DocMD's Medline access page.
Overview of HIT
Pediatric patients and HIT
Temporal aspects of HIT
von Willebrand Disease
Protocol
Hemostatic Drug Information Links
Abciximab (ReoPro) - click ReoPro
Adverse drug reactions - Click Adversereactions.com
Aprotinin (trasylol) - Click trasylol
Argatroban - Click argatroban.com
For.hemophilia.immunedisorders.shock- Click www.alphather.com
Bivalurdin (Angiomax)-Click www.angiomax.com
Clopidogrel (Plavix)-Click www.plavix.com
Danaproid (Orgaran)-Click www.orgaran.com
Enoxaparin (Lovenox)-Click www.lovenox.com
Epoetin alfa (Procrit)-Click www.procrit.com
Recombinant factor VIIa (Novoseven)-Click Factorviia.com
Lepirudin, recombinant hirudin (Refludan)-Click www.refludan.com
Platelet inhibitors-Click PlateletInhibitors.com
Protamine-Click Protamine
Tirofiban (Aggrastat)-Click www.aggrastat.com
warfarin (Coumadin)-Click www.coumadin.com.
Online Anticoagulation Information for Pharmacists and Patients
Anticoagulants from Wikipedia (antithrombics, fibrinolytic, and thrombolytics) are a class of drugs that work to prevent the coagulation (clotting) of blood. Such substances occur naturally in leeches and blood-sucking insects. A group of pharmaceuticals called anticoagulants can be used in vivo as a medication for thrombotic disorders. Some anticoagulants are used in medical equipment, such as test tubes, blood transfusion bags, and renal dialysis equipment.
- 1 Medications
- 2 Food and herbal supplements
- 3 General indications
- 4 Laboratory use
- 5 See also
- 6 References
- 7 External links
Medications
Anticoagulants reduce blood clotting. This prevents deep vein thrombosis, pulmonary embolism, myocardial infarction and ischemic stroke.
Coumarins (vitamin K antagonists)
Further information: Vitamin K antagonist
These oral anticoagulants are derived from coumarin, which is found in many plants. A prominent member of this class is warfarin (Coumadin). It takes at least 48 to 72 hours for the anticoagulant effect to develop. Where an immediate effect is required, heparin must be given concomitantly. These anticoagulants are used to treat patients with deep-vein thrombosis (DVT), pulmonary embolism (PE) and to prevent emboli in patients with atrial fibrillation (AF), and mechanical prosthetic heart valves.
Adverse effects
Patients aged 80 years or more may be especially susceptible to bleeding complications, with a rate of 13 bleeds per 100 person-years. These oral anticoagulants are used widely as poisons for mammalian pests, especially rodents. (For details, see rodenticide and warfarin.) Depletion of vitamin K by Coumadin therapy increases risk of arterial calcification and heart valve calcification, especially if too much vitamin D is present.
Available agents
- Warfarin (Coumadin) is the main agent used in the US and UK.
- Acenocoumarol and phenprocoumon are used more commonly outside the US and the UK.
- Atromentin
- Brodifacoum is used as rat poison, but is not used medically.
- Phenindione
- Heparin and derivative substances
Low molecular weight heparin
Low molecular weight heparin, a more highly processed product, is useful as it does not require monitoring of the APTT coagulation parameter (it has more predictable plasma levels) and has fewer side effects.
Synthetic pentasaccharide inhibitors of factor Xa
- Fondaparinux is a synthetic sugar composed of the five sugars (pentasaccharide) in heparin that bind to antithrombin. It is a smaller molecule than low molecular weight heparin.
- Idraparinux
Direct factor Xa inhibitors
Main article: Direct Xa inhibitor
Drugs such as rivaroxaban, apixaban and edoxaban work by inhibiting factor Xa directly (unlike the heparins and fondaparinux, which work via antithrombin activation). Also betrixaban (LY517717) from Portola Pharmaceuticals, darexaban (YM150) from Astellas and more recent TAK-442 letaxaban (Takeda) and eribaxaban (PD0348292) (Pfizer). The development of darexaban was discontinued in September 2011: in a trial for prevention of recurrences of myocardial infarction in top of dual antiplatelet therapy, the drug didn't work and the risk for bleeding was increased bij 300%. The development of letaxaban was discontinued for acute coronary syndrome in May 2011 following negative results from a Phase II study.
Heparin-induced thrombocytopenia (HIT)
Heparin-induced thrombocytopenia (HIT) is the development of thrombocytopenia (a low platelet count), due to the administration of various forms of heparin, an anticoagulant. HIT predisposes to thrombosis, the abnormal formation of blood clots inside a blood vessel, and when thrombosis is identified the condition is called heparin-induced thrombocytopenia and thrombosis (HITT). HIT is caused by the formation of abnormal antibodies that activate platelets. If someone receiving heparin develops new or worsening thrombosis, or if the platelet count falls, HIT can be confirmed with specific blood tests.
The treatment of HIT requires both protection from thrombosis and choice of an agent that will not reduce the platelet count further. Several agents exist for this purpose, mainly lepirudin and argatroban. While heparin was discovered in the 1930s, HIT was not reported until the 1960s and 1970s.
Treatment
Molecular structure of argatroban, a direct thrombin inhibitor used as an alternative to heparin in HIT. Given the fact that HIT predisposes strongly to new episodes of thrombosis, it is not sufficient to simply discontinue the heparin administration. Generally, an alternative anticoagulant is needed to suppress the thrombotic tendency while the generation of antibodies stops and the platelet count recovers. To make matters more complicated, the other most commonly used anticoagulant, warfarin, should not be used in HIT until the platelet count is at least 150 x 10^9/L because there is a very high risk of warfarin necrosis in people with HIT who have low platelet counts. Warfarin necrosis is the development of skin gangrene in those receiving warfarin or a similar vitamin K inhibitor. If the patient was receiving warfarin at the time when HIT is diagnosed, the activity of warfarin is reversed with vitamin K. Transfusing platelets is discouraged, as there is a theoretical risk that this may worsen the risk of thrombosis; the platelet count is rarely low enough to be the principal cause of significant hemorrhage.
Three agents are used to provide anticoagulation in patients with strongly suspected or proven HIT: danaparoid, lepirudin, and argatroban. These are alternatives to heparin therapy. Not all agents are registered in all countries. For instance, argatroban is not used in the United Kingdom and danaparoid is not available in the United States. Lepirudin production stopped on May 31, 2012. A fourth agent acting as a Factor Xa inhibitor also has an off label use for HIT treatment known as fondaparinux and is available and commonly used in the United States.
According to systematic review, patients treated with lepirudin for HIT showed a relative risk reduction of clinical outcome (death, amputation, etc.) to be 0.52 and 0.42 when compared to patient controls. In addition, patients treated with argatroban for HIT showed a relative risk reduction of the above clinical outcomes to be 0.20 and 0.18.
Direct thrombin inhibitors
Main article: direct thrombin inhibitor
Another type of anticoagulant is the direct thrombin inhibitor. Current members of this class include the bivalent drugs hirudin, lepirudin, and bivalirudin; and the monovalent drugs argatroban and dabigatran. An oral direct thrombin inhibitor, ximelagatran (Exanta) was denied approval by the Food and Drug Administration (FDA) in September 2004 and was pulled from the market entirely in February 2006 after reports of severe liver damage and heart attacks. In November 2010, dabigatran was approved by the FDA to treat atrial fibrillation.
Antithrombin protein therapeutics
The antithrombin protein itself is used as a protein therapeutic that can be purified from human plasma or produced recombinantly (for example, Atryn, which is produced in the milk of genetically modified goats.)
Antithrombin is approved by the FDA as an anticoagulant for the prevention of clots before, during, or after surgery or birthing in patients with hereditary antithrombin deficiency.
Other types of anticoagulants
Many other anticoagulants exist, for use in research and development, diagnostics, or as drug candidates.
- Batroxobin, a toxin from a snake venom, clots platelet-rich plasma without affecting platelet functions (lyses fibrinogen).
- Hementin is an anticoagulant protease from the salivary glands of the giant Amazon leech, Haementeria ghilianii.
Anticoagulation Related Websiles
AF Answers: What is Atrial Fibrillation
Agency for Healthcare Research and Quality: Blood Thinner Pills
American Stroke Association
Anticoagulant and Antiplatelet Drugs
Antithrombotic Therapy and Prevention of Thrombosis
Anticoagulant Treatment
Anticoagulation - American Heart Association
Anticoagulation Articles
Anticoagulation Resource Center
Anticoagulation Therapy - Anticoagulation Europe
ClotCare Online Resource
Coumadin (warfarin sodium tablet, USP) Crystalline
EHRA Practical Guide on the use of new oral anticoagulants
Guide to Anticoagulant Therapy: Heparin
Guidelines For Antithrombotic Therapy
LOVENOX® (enoxaparin sodium injection) Dosing for DVT
Lovenox® (enoxaparin sodium injection) Product Information
Lovenox (Enoxaparin Sodium Injection) Drug Information
MedicineNet.com: Warfarin (Coumadin)
New Oral Anticoagulants for Atrial Fibrillation
New oral anticoagulants: which one should my patient use?
Outpatient Management of Anticoagulation Therapy - American What is Pradaxa
Pharmacology –What’s New in Anticoagulation Medications
Pradaxa Information
Review: New Oral Anticoagulants for Afib, VTE, and ACS -
The Coalition to Prevent Deep-Vein Thrombosis (DVT)
XARELTO® (rivaroxaban)
XARELTO®
Warfarin and Beyond: An Update On Oral Anticoagulation Therapy
Adult Anticoagulation Orders Following Placement of Impella®
IMPELLA 2.5 ADDENDUM TO ADULT CRITICAL CARE ... - InfoClique
Use of the Impella 2.5 in High-Risk Percutaneous Coronary
Unfractionated Heparin Infusion Protocol - University Health System
Principles of Impella Cardiac Support - Cardiac Interventions Today
The Duration of Impella 2.5 Circulatory Support and Length of
Anticoagulation Protocols
Heparin & Enoxaparin - VUNeo.Org
Transition of Anticoagulants 2014 - Thomas Land Publishers
(BESt). Management of low molecular weight heparin therapy
University of Connecticut Health Center- John ... - Pharmacy
Anticoagulation Therapy Guidelines for Medical Indications
Guidelines For Antithrombotic Therapy
Guidelines for Deep Venous Thrombosis (DVT) Prophylaxis
Anticoagulation Bridging - Intermountain Physician
Pharmacokinetics of the low molecular weight heparin
Heparin Induced Thrombocytopenia Related Links
American Association of Blood Banks
American Red Cross
BleedingWeb.com
Bloodline
Blood management abstracts (SABM).
California Blood Bank Society
Factor VIIa
Haemophilia Forum
Heparin Induced Thrombocytopenia
International Society on Thrombosis and Haemostasis.
Irontherapy.org
Lipids Online
Management of anticoagulation, an anticoagulation management service.
DocMD's SpecialtyLinks
DocMD's Medline access page.
National Heart Lung and Blood Institute at the NIH
Network for Advancement of Transfusion Alternatives.
National Organization for Rare Disorders.
National Hemophilia Foundation's web site
Platelet inhibitors
Novoseven
Plasma Protein Therapeutics Association (PPTA)
Regional anesthesia guidelines
Resource guide
Scientific slides
Spanish language information and sites on hemostasis.
Society for the Advancement of Blood Management
CABG-consult.com.
Hemostasiscme.org.
Transfusion Medicine and Alternatives in Transfusion Medicine
Trigger
VascularWeb
Web based illustrations about hemostasis from diaPharma site.
Heparin Induced Thrombocytopenia.
Heparin Induced Thrombocytopenia (HIT)
Hit Related Links
American Red Cross
Frequently asked questions about HIT
HIT and cardiopulmonary bypass
HIT guidelines
HIT information
Incidence of HIT
Heparin Induced Thrombocytopenia
DocMD's Medline access page.
Overview of HIT
Pediatric patients and HIT
Temporal aspects of HIT
von Willebrand Disease
Protocol
Hemostatic Drug Information Links
Abciximab (ReoPro) - click ReoPro
Adverse drug reactions - Click Adversereactions.com
Aprotinin (trasylol) - Click trasylol
Argatroban - Click argatroban.com
For.hemophilia.immunedisorders.shock- Click www.alphather.com
Bivalurdin (Angiomax)-Click www.angiomax.com
Clopidogrel (Plavix)-Click www.plavix.com
Danaproid (Orgaran)-Click www.orgaran.com
Enoxaparin (Lovenox)-Click www.lovenox.com
Epoetin alfa (Procrit)-Click www.procrit.com
Recombinant factor VIIa (Novoseven)-Click Factorviia.com
Lepirudin, recombinant hirudin (Refludan)-Click www.refludan.com
Platelet inhibitors-Click PlateletInhibitors.com
Protamine-Click Protamine
Tirofiban (Aggrastat)-Click www.aggrastat.com
warfarin (Coumadin)-Click www.coumadin.com.